ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000297

Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia

Identifieur interne : 000297 ( PascalFrancis/Corpus ); précédent : 000296; suivant : 000298

Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia

Auteurs : Richard Camicioli ; Jennifer Sabino ; Myrlene Gee ; Thomas Bouchard ; Nancy Fisher ; Chris Hanstock ; Derek Emery ; W. R. Wayne Martin

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0353361

Descripteurs français

Pascal (Inist)
- Atrophie, Maladie de Parkinson, Démence, Pathologie du système nerveux, Dilatation, Encéphale, Homme, Imagerie RMN.

English descriptors

KwdEn :
- Atrophy, Dementia, Dilatation, Encephalon, Human, Nervous system diseases, Nuclear magnetic resonance imaging, Parkinson disease.

Abstract

Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia`
A11	`01`	`1`		`@1 CAMICIOLI (Richard)`
A11	`02`	`1`		`@1 SABINO (Jennifer)`
A11	`03`	`1`		`@1 GEE (Myrlene)`
A11	`04`	`1`		`@1 BOUCHARD (Thomas)`
A11	`05`	`1`		`@1 FISHER (Nancy)`
A11	`06`	`1`		`@1 HANSTOCK (Chris)`
A11	`07`	`1`		`@1 EMERY (Derek)`
A11	`08`	`1`		`@1 WAYNE MARTIN (W. R.)`
A14	`01`			`@1 Department of Medicine (Neurology), University of Alberta @2 Edmonton, Alberta @3 CAN @Z 1 aut. @Z 4 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Biomedical Engineering, University of Alberta @2 Edmonton, Alberta @3 CAN @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 Department of Medicine, University of Calgary @2 Calgary, Alberta @3 CAN @Z 4 aut.`
A14	`04`			`@1 Division of Neurosciences, Alberta Health Services @2 Edmonton, Alberta @3 CAN @Z 5 aut.`
A14	`05`			`@1 Department of Radiology and Diagnostic Imaging, University of Alberta @2 Edmonton, Alberta @3 CAN @Z 7 aut.`
A20				`@1 1443-1450`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000508552620110`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 37 ref.`
A47	`01`	`1`		`@0 11-0353361`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Atrophie @5 01`
C03	`01`	`X`	`ENG`	`@0 Atrophy @5 01`
C03	`01`	`X`	`SPA`	`@0 Atrofia @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Démence @5 03`
C03	`03`	`X`	`ENG`	`@0 Dementia @5 03`
C03	`03`	`X`	`SPA`	`@0 Demencia @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Dilatation @5 09`
C03	`05`	`X`	`ENG`	`@0 Dilatation @5 09`
C03	`05`	`X`	`SPA`	`@0 Dilatación @5 09`
C03	`06`	`X`	`FRE`	`@0 Encéphale @5 10`
C03	`06`	`X`	`ENG`	`@0 Encephalon @5 10`
C03	`06`	`X`	`SPA`	`@0 Encéfalo @5 10`
C03	`07`	`X`	`FRE`	`@0 Homme @5 11`
C03	`07`	`X`	`ENG`	`@0 Human @5 11`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`08`	`X`	`FRE`	`@0 Imagerie RMN @5 12`
C03	`08`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 12`
C03	`08`	`X`	`SPA`	`@0 Imaginería RMN @5 12`
C07	`01`	`X`	`FRE`	`@0 Système nerveux central @5 37`
C07	`01`	`X`	`ENG`	`@0 Central nervous system @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso central @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 241`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0353361 INIST
ET :	Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia
AU :	CAMICIOLI (Richard); SABINO (Jennifer); GEE (Myrlene); BOUCHARD (Thomas); FISHER (Nancy); HANSTOCK (Chris); EMERY (Derek); WAYNE MARTIN (W. R.)
AF :	Department of Medicine (Neurology), University of Alberta/Edmonton, Alberta/Canada (1 aut., 4 aut., 8 aut.); Department of Biomedical Engineering, University of Alberta/Edmonton, Alberta/Canada (2 aut., 3 aut., 6 aut., 7 aut.); Department of Medicine, University of Calgary/Calgary, Alberta/Canada (4 aut.); Division of Neurosciences, Alberta Health Services/Edmonton, Alberta/Canada (5 aut.); Department of Radiology and Diagnostic Imaging, University of Alberta/Edmonton, Alberta/Canada (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 8; Pp. 1443-1450; Bibl. 37 ref.
LA :	Anglais
EA :	Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.
CC :	002B17; 002B17G
FD :	Atrophie; Maladie de Parkinson; Démence; Pathologie du système nerveux; Dilatation; Encéphale; Homme; Imagerie RMN
FG :	Système nerveux central; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Atrophy; Parkinson disease; Dementia; Nervous system diseases; Dilatation; Encephalon; Human; Nuclear magnetic resonance imaging
EG :	Central nervous system; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Atrofia; Parkinson enfermedad; Demencia; Sistema nervioso patología; Dilatación; Encéfalo; Hombre; Imaginería RMN
LO :	INIST-20953.354000508552620110
ID :	11-0353361

Links to Exploration step

Pascal:11-0353361

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia</title>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sabino, Jennifer" sort="Sabino, Jennifer" uniqKey="Sabino J" first="Jennifer" last="Sabino">Jennifer Sabino</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gee, Myrlene" sort="Gee, Myrlene" uniqKey="Gee M" first="Myrlene" last="Gee">Myrlene Gee</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bouchard, Thomas" sort="Bouchard, Thomas" uniqKey="Bouchard T" first="Thomas" last="Bouchard">Thomas Bouchard</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Medicine, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fisher, Nancy" sort="Fisher, Nancy" uniqKey="Fisher N" first="Nancy" last="Fisher">Nancy Fisher</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurosciences, Alberta Health Services</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hanstock, Chris" sort="Hanstock, Chris" uniqKey="Hanstock C" first="Chris" last="Hanstock">Chris Hanstock</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emery, Derek" sort="Emery, Derek" uniqKey="Emery D" first="Derek" last="Emery">Derek Emery</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Radiology and Diagnostic Imaging, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wayne Martin, W R" sort="Wayne Martin, W R" uniqKey="Wayne Martin W" first="W. R." last="Wayne Martin">W. R. Wayne Martin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0353361</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0353361 INIST</idno>
<idno type="RBID">Pascal:11-0353361</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000297</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia</title>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sabino, Jennifer" sort="Sabino, Jennifer" uniqKey="Sabino J" first="Jennifer" last="Sabino">Jennifer Sabino</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gee, Myrlene" sort="Gee, Myrlene" uniqKey="Gee M" first="Myrlene" last="Gee">Myrlene Gee</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bouchard, Thomas" sort="Bouchard, Thomas" uniqKey="Bouchard T" first="Thomas" last="Bouchard">Thomas Bouchard</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Medicine, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fisher, Nancy" sort="Fisher, Nancy" uniqKey="Fisher N" first="Nancy" last="Fisher">Nancy Fisher</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurosciences, Alberta Health Services</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hanstock, Chris" sort="Hanstock, Chris" uniqKey="Hanstock C" first="Chris" last="Hanstock">Chris Hanstock</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emery, Derek" sort="Emery, Derek" uniqKey="Emery D" first="Derek" last="Emery">Derek Emery</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Radiology and Diagnostic Imaging, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wayne Martin, W R" sort="Wayne Martin, W R" uniqKey="Wayne Martin W" first="W. R." last="Wayne Martin">W. R. Wayne Martin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atrophy</term>
<term>Dementia</term>
<term>Dilatation</term>
<term>Encephalon</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Atrophie</term>
<term>Maladie de Parkinson</term>
<term>Démence</term>
<term>Pathologie du   système nerveux</term>
<term>Dilatation</term>
<term>Encéphale</term>
<term>Homme</term>
<term>Imagerie RMN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CAMICIOLI (Richard)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SABINO (Jennifer)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GEE (Myrlene)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BOUCHARD (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FISHER (Nancy)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HANSTOCK (Chris)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>EMERY (Derek)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WAYNE MARTIN (W. R.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Medicine (Neurology), University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Biomedical Engineering, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Medicine, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurosciences, Alberta Health Services</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Radiology and Diagnostic Imaging, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1443-1450</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508552620110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0353361</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Atrophie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Atrophy</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Atrofia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Démence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dementia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Demencia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dilatation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dilatation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dilatación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>241</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0353361 INIST</NO>
<ET>Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia</ET>
<AU>CAMICIOLI (Richard); SABINO (Jennifer); GEE (Myrlene); BOUCHARD (Thomas); FISHER (Nancy); HANSTOCK (Chris); EMERY (Derek); WAYNE MARTIN (W. R.)</AU>
<AF>Department of Medicine (Neurology), University of Alberta/Edmonton, Alberta/Canada (1 aut., 4 aut., 8 aut.); Department of Biomedical Engineering, University of Alberta/Edmonton, Alberta/Canada (2 aut., 3 aut., 6 aut., 7 aut.); Department of Medicine, University of Calgary/Calgary, Alberta/Canada (4 aut.); Division of Neurosciences, Alberta Health Services/Edmonton, Alberta/Canada (5 aut.); Department of Radiology and Diagnostic Imaging, University of Alberta/Edmonton, Alberta/Canada (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 8; Pp. 1443-1450; Bibl. 37 ref.</SO>
<LA>Anglais</LA>
<EA>Age-related ventricular enlargement is accelerated in Alzheimer's disease, but its relationship to cognitive decline in Parkinson's disease is less clear, even though dementia is common in Parkinson's disease. Our goals were to determine if greater enlargement of the ventricles and gray or white matter atrophy occurred in Parkinson's disease patients developing cognitive decline. Older nondemented patients with Parkinson's disease (33) and age- and sex-matched controls (39) were recruited and prospectively assessed for the development of significant cognitive decline over 36 months. Magnetic resonance imaging was obtained every 18 months, and ventricular volume and total brain gray and white matter volumes were measured using reliable segmentation of T1-weighted volumetric scans. Subjects with incidental intracranial abnormalities, an atypical course, and stroke as well as dropouts were excluded from a cohort of 52 patients and 50 controls. Among 33 patients and 39 controls, 10 patients and 3 controls developed significant cognitive impairment or dementia. Ventricular change and Parkinson's disease status were significantly associated with dementia. Ventricular change was significantly correlated with change in Mini-Mental Status Examination in the Parkinson's disease with dementia group (r = 0.87, P = .001). Gray matter atrophy was greater in Parkinson's disease with dementia, with similar change over time in both Parkinson's disease and Parkinson's disease with dementia. White matter volumes were not significantly different between Parkinson's disease and Parkinson's disease with dementia; however, the decrease over time might be greater in Parkinson's disease with dementia. Ventricular dilatation occurs early in the course of significant cognitive decline in patients with Parkinson's disease, possibly reflecting both cortical gray and white matter loss.</EA>
<CC>002B17; 002B17G</CC>
<FD>Atrophie; Maladie de Parkinson; Démence; Pathologie du système nerveux; Dilatation; Encéphale; Homme; Imagerie RMN</FD>
<FG>Système nerveux central; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Atrophy; Parkinson disease; Dementia; Nervous system diseases; Dilatation; Encephalon; Human; Nuclear magnetic resonance imaging</ED>
<EG>Central nervous system; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Atrofia; Parkinson enfermedad; Demencia; Sistema nervioso patología; Dilatación; Encéfalo; Hombre; Imaginería RMN</SD>
<LO>INIST-20953.354000508552620110</LO>
<ID>11-0353361</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000297 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000297 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0353361
   |texte=   Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia

Ventricular Dilatation and Brain Atrophy in Patients with Parkinson's Disease with Incipient Dementia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri